Please Wait...

PTH, Intact // Intact Parathyroid Hormone

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

PTH is produced in the parathyroid gland and is a key regulator in skeletal and mineral homeostasis. PTH is a 84 amino-acid peptide, with an helical conformation in the 1-34 portion of its binding domain to its receptor of type 1 (PTH1R) (Jin et al., 2000). PTH and PTH-related peptide (PTHrP) have highly conserved sequences and activates PTH1R. The C terminal fragments of the intact PTH, PTH(39-84) or PTH(53-84) bind another receptor CPTHR, expressed on bone cells (Divieti et al., 2001). The 1-34 portion of PTH (and the PTHrP) stimulate bone formation and increase bone mass in patients with osteoporosis (Brommage et al., 1999; Lindsay et al., 1997). On the opposite, the truncated PTH 7-34 is a low affinity agonist of the receptor PTHR1 with the C terminus part required for the high affinity binding to the receptor (Gardella et al., 1991; Jin et al., 2000). Since PTH circulates under different forms, biologically active or not, immunoassays for its measurement must be chosen with particular attention (Komaba et al., 2009; Souberbielle et al., 2006).

Several automated or manual sandwich immunoassays are employed in the laboratory for measurement in plasma and/or serum:

  • Second generation assays designed to measure the entire 1-84 amino-acid peptide in addition to the 7-84 amino-acid peptide (Intact PTH or Total PTH),
  • "Third" generation assays which measure only the 1-84 amino-acid peptide (Whole PTH or biologically active PTH) and the Amino-PTH (a post-translational form produced in parathyroid carcinomas).
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Join Bioclinica in a live #Xtalks webinar 10/31 exploring challenges & benefits of different sourcing models to man… https://t.co/kRYNc1Z3gj
bioclinica (3 hours ago)
Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s… https://t.co/j96UN9568o
bioclinica (9 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (Yesterday)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (Yesterday)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner